Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Interim Report Q1, 2019

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics’ 2018 Annual Report published

Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis

Year-end report, 2018

Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis

Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2019